Literature DB >> 17346677

HER-2/neu raises SHP-2, stops IFN-gamma anti-proliferation in bladder cancer.

Wen-Pin Su1, I-Hwi Tu, Shiao-Wen Hu, Hsuan-Heng Yeh, Dar-Bin Shieh, Tsai-Yun Chen, Wu-Chou Su.   

Abstract

Gene amplification or HER-2/neu protein overexpression signals a poor outcome for bladder cancer patients. We investigated the anti-proliferative effect of IFN-gamma in HER-2/neu-transfected human bladder cancer cells (TCC-N5 and TCC-N10). The cells continued growing after IFN-gamma stimulation but did not activate the Janus kinase (Jak)/Stat pathway. We found Jak/Stat protein phosphatase in TCC-N5 and TCC-N10 cells with upregulated Src homology 2-containing protein tyrosine phosphatase-2 (SHP-2). After the cells had been treated with AG825, a HER-2/neu-specific inhibitor, SHP-2 expression declined, and Jak2/Stat1 reactivated. Similar results were reported in a mouse bladder cancer cell line, MBT2, with constitutive HER-2/neu overexpression. Further, AG825 pretreatment restored the anti-proliferation activity of IFN-gamma in TCC-N5 and TCC-N10 cells. Therefore, the suppression of IFN-gamma signaling in HER-2/neu-overexpressing bladder cancer cells might be due to SHP-2 upregulation. The regulation of SHP-2 by HER-2/neu provides a new target for blocking the HER-2/neu oncogenic pathway.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17346677     DOI: 10.1016/j.bbrc.2007.02.099

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

Review 1.  Signal integration: a framework for understanding the efficacy of therapeutics targeting the human EGFR family.

Authors:  H Michael Shepard; Cathleen M Brdlik; Hans Schreiber
Journal:  J Clin Invest       Date:  2008-11       Impact factor: 14.808

Review 2.  The role and target potential of protein tyrosine phosphatases in cancer.

Authors:  Taolin Yi; Daniel Lindner
Journal:  Curr Oncol Rep       Date:  2008-03       Impact factor: 5.075

3.  SHP2 is overexpressed and inhibits pSTAT1-mediated APM component expression, T-cell attracting chemokine secretion, and CTL recognition in head and neck cancer cells.

Authors:  Michael S Leibowitz; Raghvendra M Srivastava; Pedro A Andrade Filho; Ann Marie Egloff; Lin Wang; Raja R Seethala; Soldano Ferrone; Robert L Ferris
Journal:  Clin Cancer Res       Date:  2013-01-30       Impact factor: 12.531

Review 4.  Progress in the Research and Targeted Therapy of ErbB/HER Receptors in Urothelial Bladder Cancer.

Authors:  Dong Chen; Yunlin Ye; Shengjie Guo; Kao Yao
Journal:  Front Mol Biosci       Date:  2021-12-23
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.